| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 14 | 2022 | 1378 | 1.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 9 | 2019 | 1374 | 0.860 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 10 | 2024 | 1405 | 0.800 |
Why?
|
| Vincristine | 8 | 2024 | 1036 | 0.770 |
Why?
|
| Central Nervous System Neoplasms | 7 | 2023 | 916 | 0.710 |
Why?
|
| Lymphoma, Follicular | 5 | 2017 | 457 | 0.660 |
Why?
|
| Electronic Mail | 1 | 2020 | 213 | 0.630 |
Why?
|
| Vidarabine | 5 | 2024 | 336 | 0.630 |
Why?
|
| Lymphoma | 7 | 2023 | 1901 | 0.610 |
Why?
|
| Cyclophosphamide | 13 | 2024 | 2220 | 0.610 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 | 2024 | 1640 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2024 | 11742 | 0.590 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2020 | 333 | 0.580 |
Why?
|
| Documentation | 1 | 2020 | 897 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 5 | 2017 | 940 | 0.450 |
Why?
|
| Neoplasm Staging | 14 | 2020 | 11120 | 0.450 |
Why?
|
| Doxorubicin | 8 | 2024 | 2224 | 0.430 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2023 | 301 | 0.430 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 34 | 0.430 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 111 | 0.420 |
Why?
|
| Machado-Joseph Disease | 1 | 2012 | 26 | 0.400 |
Why?
|
| Prednisone | 7 | 2024 | 1563 | 0.380 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2023 | 678 | 0.380 |
Why?
|
| Electronic Health Records | 3 | 2020 | 4811 | 0.370 |
Why?
|
| Medical Oncology | 6 | 2022 | 2321 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2023 | 5672 | 0.350 |
Why?
|
| Methotrexate | 6 | 2015 | 1719 | 0.350 |
Why?
|
| Anthracyclines | 3 | 2023 | 284 | 0.340 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2011 | 168 | 0.340 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 646 | 0.320 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2024 | 1469 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 7 | 2014 | 694 | 0.300 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 621 | 0.300 |
Why?
|
| Breast Implants | 1 | 2011 | 411 | 0.290 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 592 | 0.290 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2006 | 16 | 0.270 |
Why?
|
| Patient Care | 1 | 2012 | 622 | 0.270 |
Why?
|
| Transplantation Conditioning | 6 | 2014 | 1590 | 0.260 |
Why?
|
| Bleomycin | 1 | 2007 | 494 | 0.260 |
Why?
|
| Neoplasms | 12 | 2022 | 22173 | 0.260 |
Why?
|
| Erythema | 1 | 2007 | 262 | 0.250 |
Why?
|
| Neutropenia | 4 | 2019 | 885 | 0.250 |
Why?
|
| Transplantation Chimera | 5 | 2004 | 594 | 0.250 |
Why?
|
| Remission Induction | 8 | 2019 | 2397 | 0.240 |
Why?
|
| Middle Aged | 68 | 2024 | 220921 | 0.240 |
Why?
|
| Waldenstrom Macroglobulinemia | 5 | 2014 | 1073 | 0.240 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2006 | 178 | 0.230 |
Why?
|
| Stem Cell Transplantation | 5 | 2018 | 1600 | 0.220 |
Why?
|
| Hospitalization | 8 | 2020 | 10721 | 0.220 |
Why?
|
| Disease-Free Survival | 13 | 2018 | 6815 | 0.210 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2023 | 237 | 0.210 |
Why?
|
| Adenine | 3 | 2024 | 987 | 0.210 |
Why?
|
| Positron-Emission Tomography | 6 | 2016 | 6484 | 0.200 |
Why?
|
| Recurrence | 11 | 2018 | 8466 | 0.200 |
Why?
|
| Humans | 113 | 2024 | 761596 | 0.200 |
Why?
|
| Piperidines | 4 | 2024 | 1656 | 0.200 |
Why?
|
| Pyrimidines | 6 | 2021 | 3028 | 0.200 |
Why?
|
| Leukopoiesis | 1 | 2001 | 54 | 0.190 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 111 | 0.190 |
Why?
|
| Busulfan | 5 | 2017 | 258 | 0.190 |
Why?
|
| Antigens, CD19 | 1 | 2024 | 424 | 0.190 |
Why?
|
| Fund Raising | 1 | 2021 | 49 | 0.190 |
Why?
|
| Male | 75 | 2024 | 360846 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 5 | 2003 | 2693 | 0.180 |
Why?
|
| Gene Rearrangement | 3 | 2017 | 1125 | 0.180 |
Why?
|
| Aged | 49 | 2024 | 169310 | 0.180 |
Why?
|
| Oncogenes | 2 | 2017 | 1222 | 0.180 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2009 | 263 | 0.180 |
Why?
|
| Graft vs Host Disease | 10 | 2018 | 3029 | 0.180 |
Why?
|
| Female | 70 | 2024 | 392705 | 0.180 |
Why?
|
| Adult | 55 | 2024 | 221210 | 0.180 |
Why?
|
| Drug Hypersensitivity | 2 | 2021 | 917 | 0.170 |
Why?
|
| Data Mining | 2 | 2015 | 551 | 0.160 |
Why?
|
| Symporters | 1 | 2022 | 363 | 0.160 |
Why?
|
| Capillaries | 2 | 2019 | 755 | 0.160 |
Why?
|
| Lymphocyte Depletion | 5 | 2004 | 602 | 0.160 |
Why?
|
| Microscopy, Video | 1 | 2019 | 241 | 0.160 |
Why?
|
| Transplantation, Autologous | 7 | 2023 | 2115 | 0.160 |
Why?
|
| Burkitt Lymphoma | 2 | 2011 | 335 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2004 | 686 | 0.150 |
Why?
|
| Vinblastine | 1 | 2019 | 488 | 0.150 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 256 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 840 | 0.140 |
Why?
|
| Treatment Outcome | 24 | 2024 | 64685 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2018 | 20568 | 0.130 |
Why?
|
| Dacarbazine | 1 | 2019 | 559 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 3206 | 0.130 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 4853 | 0.130 |
Why?
|
| Biopsy | 5 | 2017 | 6766 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 1459 | 0.130 |
Why?
|
| Hydronephrosis | 1 | 2017 | 271 | 0.130 |
Why?
|
| Massachusetts | 5 | 2020 | 8833 | 0.130 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 354 | 0.130 |
Why?
|
| Transplantation, Homologous | 10 | 2018 | 4807 | 0.130 |
Why?
|
| Natural Language Processing | 2 | 2015 | 1163 | 0.130 |
Why?
|
| Combined Modality Therapy | 7 | 2017 | 8527 | 0.120 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 270 | 0.120 |
Why?
|
| Central Nervous System | 2 | 2023 | 1336 | 0.120 |
Why?
|
| H-Y Antigen | 2 | 2004 | 42 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 1406 | 0.120 |
Why?
|
| Palliative Care | 3 | 2020 | 3598 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 8554 | 0.120 |
Why?
|
| Prognosis | 14 | 2020 | 29629 | 0.120 |
Why?
|
| Lichen Planus, Oral | 1 | 2014 | 57 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2018 | 1596 | 0.110 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2013 | 40 | 0.110 |
Why?
|
| Telemedicine | 2 | 2023 | 3052 | 0.110 |
Why?
|
| Hematopoiesis | 2 | 2002 | 2050 | 0.110 |
Why?
|
| Aged, 80 and over | 18 | 2019 | 58984 | 0.110 |
Why?
|
| Physicians | 2 | 2022 | 4591 | 0.110 |
Why?
|
| Tacrolimus | 3 | 2015 | 733 | 0.110 |
Why?
|
| Back Pain | 1 | 2017 | 545 | 0.110 |
Why?
|
| Edema | 1 | 2017 | 766 | 0.110 |
Why?
|
| Sarcopenia | 1 | 2018 | 372 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 125 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2017 | 744 | 0.100 |
Why?
|
| Retrospective Studies | 20 | 2024 | 80647 | 0.100 |
Why?
|
| Lymphocyte Transfusion | 3 | 2002 | 232 | 0.100 |
Why?
|
| Polyneuropathies | 1 | 2014 | 137 | 0.100 |
Why?
|
| Jaundice | 1 | 2013 | 94 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 718 | 0.100 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2014 | 155 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2021 | 2009 | 0.100 |
Why?
|
| Sirolimus | 4 | 2015 | 1533 | 0.100 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2017 | 1363 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2015 | 544 | 0.100 |
Why?
|
| Leg | 1 | 2017 | 1088 | 0.100 |
Why?
|
| Cross Infection | 1 | 2021 | 1422 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2019 | 4021 | 0.100 |
Why?
|
| Silicone Gels | 1 | 2011 | 39 | 0.100 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 432 | 0.100 |
Why?
|
| Enteropathy-Associated T-Cell Lymphoma | 1 | 2011 | 13 | 0.100 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 574 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 304 | 0.090 |
Why?
|
| Diagnosis, Differential | 5 | 2017 | 12973 | 0.090 |
Why?
|
| Pelvic Bones | 1 | 1993 | 270 | 0.090 |
Why?
|
| Thiotepa | 3 | 2017 | 66 | 0.090 |
Why?
|
| Follow-Up Studies | 10 | 2024 | 39106 | 0.090 |
Why?
|
| Hospice Care | 1 | 2017 | 678 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 21019 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 2013 | 401 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2023 | 2781 | 0.090 |
Why?
|
| Nerve Fibers | 1 | 2014 | 708 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 935 | 0.090 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 57 | 0.090 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2010 | 91 | 0.090 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 376 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2020 | 8633 | 0.090 |
Why?
|
| Microfluidics | 1 | 2015 | 653 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2011 | 15633 | 0.080 |
Why?
|
| Length of Stay | 3 | 2018 | 6426 | 0.080 |
Why?
|
| T-Lymphocytes | 4 | 2023 | 10194 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2017 | 988 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 1379 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 1486 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 13381 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2016 | 757 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2020 | 1835 | 0.080 |
Why?
|
| Immunosuppressive Agents | 3 | 2009 | 4176 | 0.080 |
Why?
|
| Myeloablative Agonists | 1 | 2009 | 209 | 0.080 |
Why?
|
| Immunoconjugates | 1 | 2016 | 953 | 0.080 |
Why?
|
| Body Composition | 1 | 2018 | 2426 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2012 | 629 | 0.080 |
Why?
|
| Hematologic Diseases | 2 | 2019 | 496 | 0.080 |
Why?
|
| Interleukin-2 | 3 | 2004 | 1889 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2020 | 3271 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 2014 | 705 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2006 | 15936 | 0.070 |
Why?
|
| Lung | 1 | 2006 | 10002 | 0.070 |
Why?
|
| Ventricular Function, Left | 2 | 2023 | 3879 | 0.070 |
Why?
|
| Lymph Nodes | 3 | 2017 | 3465 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 4758 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 1993 | 1152 | 0.070 |
Why?
|
| Disease Progression | 5 | 2012 | 13510 | 0.070 |
Why?
|
| Ascitic Fluid | 1 | 2007 | 189 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2013 | 1892 | 0.070 |
Why?
|
| Optic Nerve Diseases | 1 | 2010 | 342 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 2571 | 0.070 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1993 | 807 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2004 | 3733 | 0.070 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 13642 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2016 | 2009 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 2897 | 0.070 |
Why?
|
| Immunophenotyping | 4 | 2016 | 1869 | 0.070 |
Why?
|
| Exotoxins | 2 | 1997 | 121 | 0.070 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 1204 | 0.070 |
Why?
|
| Herpesviridae Infections | 1 | 2007 | 270 | 0.060 |
Why?
|
| Cause of Death | 2 | 2017 | 3683 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2007 | 255 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2004 | 4580 | 0.060 |
Why?
|
| Pericardial Effusion | 1 | 2007 | 247 | 0.060 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 520 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2017 | 3443 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2012 | 9280 | 0.060 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2004 | 431 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 5672 | 0.060 |
Why?
|
| Pleural Effusion | 1 | 2007 | 341 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 662 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2012 | 10451 | 0.050 |
Why?
|
| Thiazoles | 1 | 2011 | 1517 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2017 | 5293 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2004 | 253 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 15502 | 0.050 |
Why?
|
| Isoantibodies | 2 | 2004 | 674 | 0.050 |
Why?
|
| Mastectomy | 1 | 2011 | 1822 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 15843 | 0.050 |
Why?
|
| Retina | 1 | 2014 | 2659 | 0.050 |
Why?
|
| Celiac Disease | 1 | 2011 | 821 | 0.050 |
Why?
|
| Piperazines | 2 | 2004 | 2523 | 0.050 |
Why?
|
| Risk | 2 | 2016 | 9610 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2015 | 3807 | 0.050 |
Why?
|
| Mutation | 3 | 2019 | 30053 | 0.050 |
Why?
|
| Echocardiography | 1 | 2015 | 4989 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 1052 | 0.050 |
Why?
|
| Young Adult | 11 | 2020 | 59260 | 0.050 |
Why?
|
| Breast | 1 | 2011 | 1967 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2014 | 5305 | 0.050 |
Why?
|
| Methods | 1 | 2002 | 1067 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2014 | 2510 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5314 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2013 | 3606 | 0.050 |
Why?
|
| Perceptual Masking | 1 | 1982 | 90 | 0.050 |
Why?
|
| Heart Failure | 2 | 2023 | 11671 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2013 | 2330 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2006 | 672 | 0.050 |
Why?
|
| Reoperation | 1 | 2011 | 4303 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 1993 | 2046 | 0.050 |
Why?
|
| Cytarabine | 2 | 2014 | 698 | 0.050 |
Why?
|
| Adolescent | 10 | 2020 | 88326 | 0.040 |
Why?
|
| Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2018 | 4575 | 0.040 |
Why?
|
| Skin | 1 | 2014 | 4484 | 0.040 |
Why?
|
| Censuses | 1 | 2021 | 202 | 0.040 |
Why?
|
| Radiography | 2 | 2006 | 6965 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 15266 | 0.040 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 14665 | 0.040 |
Why?
|
| Fatigue | 2 | 2020 | 1552 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2024 | 12341 | 0.040 |
Why?
|
| Survival Analysis | 4 | 2019 | 10090 | 0.040 |
Why?
|
| Inpatients | 2 | 2021 | 2548 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 2006 | 649 | 0.040 |
Why?
|
| Cohort Studies | 7 | 2019 | 41495 | 0.040 |
Why?
|
| Depression | 1 | 2018 | 8126 | 0.040 |
Why?
|
| Psychometrics | 2 | 2019 | 3065 | 0.040 |
Why?
|
| Dyspnea | 1 | 2006 | 1347 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 12149 | 0.040 |
Why?
|
| Salvage Therapy | 3 | 2011 | 1263 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6484 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 1667 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 851 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3779 | 0.040 |
Why?
|
| Asthma | 1 | 2016 | 6234 | 0.040 |
Why?
|
| Self Report | 2 | 2019 | 3725 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 1784 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 1588 | 0.030 |
Why?
|
| Home Infusion Therapy | 1 | 2016 | 18 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2003 | 2557 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 9177 | 0.030 |
Why?
|
| Survival Rate | 4 | 2015 | 12723 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1008 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2002 | 962 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2019 | 647 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2022 | 54423 | 0.030 |
Why?
|
| Sex Factors | 2 | 2021 | 10554 | 0.030 |
Why?
|
| Incidence | 4 | 2018 | 21355 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2018 | 640 | 0.030 |
Why?
|
| Stroke Volume | 2 | 2023 | 5496 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1997 | 562 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2013 | 2643 | 0.030 |
Why?
|
| Desensitization, Immunologic | 1 | 2021 | 556 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 481 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2002 | 4369 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2002 | 1784 | 0.030 |
Why?
|
| United States | 4 | 2021 | 72340 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5337 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 371 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2016 | 357 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2015 | 191 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 1995 | 90 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3597 | 0.030 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2015 | 150 | 0.030 |
Why?
|
| Immunotoxins | 1 | 1995 | 175 | 0.030 |
Why?
|
| Hospices | 1 | 2017 | 245 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 23447 | 0.030 |
Why?
|
| World Health Organization | 2 | 2011 | 1322 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2015 | 322 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 314 | 0.030 |
Why?
|
| Genes, myc | 1 | 2015 | 390 | 0.030 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 105 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2002 | 22176 | 0.030 |
Why?
|
| Unified Medical Language System | 1 | 2014 | 89 | 0.030 |
Why?
|
| Physician's Role | 1 | 2020 | 917 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 453 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2017 | 11530 | 0.030 |
Why?
|
| Visual Perception | 1 | 1982 | 1389 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Microcirculation | 1 | 2018 | 1272 | 0.030 |
Why?
|
| Endocytosis | 1 | 1997 | 957 | 0.030 |
Why?
|
| Narration | 1 | 2015 | 219 | 0.030 |
Why?
|
| Periodicity | 1 | 2014 | 348 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 855 | 0.030 |
Why?
|
| Acetylation | 1 | 2015 | 1055 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 368 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2014 | 556 | 0.030 |
Why?
|
| Hepatorenal Syndrome | 1 | 2013 | 76 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1943 | 0.020 |
Why?
|
| Electroretinography | 1 | 2014 | 525 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 3826 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2021 | 1979 | 0.020 |
Why?
|
| Exanthema | 1 | 2016 | 503 | 0.020 |
Why?
|
| Rupture | 1 | 1993 | 443 | 0.020 |
Why?
|
| Pandemics | 2 | 2022 | 8656 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2017 | 1139 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 4740 | 0.020 |
Why?
|
| Virulence Factors | 1 | 1995 | 513 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2016 | 1187 | 0.020 |
Why?
|
| Eye | 1 | 1995 | 712 | 0.020 |
Why?
|
| Aspergillus fumigatus | 1 | 1992 | 157 | 0.020 |
Why?
|
| Secondary Prevention | 2 | 2011 | 1475 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 1519 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2011 | 232 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2023 | 3600 | 0.020 |
Why?
|
| Cauda Equina | 1 | 2010 | 45 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4347 | 0.020 |
Why?
|
| Age Factors | 2 | 2018 | 18399 | 0.020 |
Why?
|
| Aspergillosis | 1 | 1992 | 242 | 0.020 |
Why?
|
| Indoles | 1 | 2018 | 1833 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 10766 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 1502 | 0.020 |
Why?
|
| Leukocytes | 1 | 2018 | 2026 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 16990 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1551 | 0.020 |
Why?
|
| Time Factors | 4 | 2010 | 39969 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 2217 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2015 | 1393 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 993 | 0.020 |
Why?
|
| Etoposide | 1 | 2011 | 634 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3605 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2020 | 2521 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 416 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 2917 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1991 | 461 | 0.020 |
Why?
|
| Proteins | 1 | 2003 | 6032 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2014 | 1059 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2018 | 1937 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1968 | 151 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2508 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 1171 | 0.020 |
Why?
|
| Behavior | 1 | 1991 | 541 | 0.020 |
Why?
|
| Genotype | 1 | 2002 | 12990 | 0.020 |
Why?
|
| Benzamides | 2 | 2004 | 1371 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 603 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 534 | 0.020 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2009 | 220 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 2020 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2011 | 491 | 0.020 |
Why?
|
| Hematologic Neoplasms | 3 | 2004 | 1896 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5247 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2016 | 42232 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 1948 | 0.020 |
Why?
|
| Immune System | 2 | 2002 | 796 | 0.020 |
Why?
|
| Quality of Life | 2 | 2019 | 13367 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 36426 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 2650 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2297 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 4576 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 1609 | 0.020 |
Why?
|
| Optic Disk | 1 | 2010 | 421 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 2049 | 0.020 |
Why?
|
| Cocaine | 1 | 1991 | 958 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 6075 | 0.020 |
Why?
|
| Internationality | 1 | 2011 | 1001 | 0.020 |
Why?
|
| Terminal Care | 1 | 2017 | 1761 | 0.020 |
Why?
|
| Neutrophils | 1 | 2018 | 3767 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 4111 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2006 | 161 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7828 | 0.020 |
Why?
|
| Anxiety | 1 | 2020 | 4573 | 0.020 |
Why?
|
| Histones | 1 | 2015 | 2580 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 4243 | 0.010 |
Why?
|
| Child | 4 | 2016 | 80158 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 1809 | 0.010 |
Why?
|
| HIV Infections | 2 | 2011 | 17354 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2011 | 1498 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 3878 | 0.010 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 2791 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1968 | 803 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2002 | 5146 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 20100 | 0.010 |
Why?
|
| Cytogenetics | 1 | 2004 | 198 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 2004 | 433 | 0.010 |
Why?
|
| Infant | 3 | 2016 | 36193 | 0.010 |
Why?
|
| Tissue Donors | 2 | 2003 | 2332 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 2004 | 6312 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 3359 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 11122 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1992 | 2199 | 0.010 |
Why?
|
| Anemia | 1 | 2012 | 1509 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4317 | 0.010 |
Why?
|
| Protein Binding | 1 | 2015 | 9353 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 3639 | 0.010 |
Why?
|
| Globins | 1 | 2003 | 404 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3801 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2017 | 23996 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2010 | 1530 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2011 | 1819 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2002 | 155 | 0.010 |
Why?
|
| Syndrome | 1 | 2009 | 3267 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2003 | 293 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 1182 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 712 | 0.010 |
Why?
|
| Graft Survival | 2 | 2004 | 3820 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 9001 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2003 | 12794 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2002 | 270 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 2201 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2006 | 1218 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 1060 | 0.010 |
Why?
|
| Consensus | 1 | 2011 | 3124 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1992 | 2091 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 11076 | 0.010 |
Why?
|
| Probability | 1 | 2006 | 2477 | 0.010 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2003 | 384 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2018 | 12953 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 1991 | 0.010 |
Why?
|
| Haplotypes | 1 | 2006 | 2713 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2013 | 5971 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 2003 | 683 | 0.010 |
Why?
|
| Steroids | 1 | 2004 | 929 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 1659 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 799 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 1351 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2014 | 7968 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 1596 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9610 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2013 | 4235 | 0.010 |
Why?
|
| Registries | 1 | 2014 | 8225 | 0.010 |
Why?
|
| Liver | 1 | 2013 | 7528 | 0.010 |
Why?
|
| Risk Factors | 2 | 2015 | 74213 | 0.010 |
Why?
|
| Epitopes | 1 | 2003 | 2503 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 3442 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12690 | 0.010 |
Why?
|
| Pattern Recognition, Visual | 1 | 1982 | 823 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 1844 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12463 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2012 | 26202 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 6864 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 1995 | 150 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 2417 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1995 | 413 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 2418 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 3162 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17904 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 1995 | 313 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 7237 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2004 | 5485 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 2547 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 2639 | 0.010 |
Why?
|
| DNA Primers | 1 | 1997 | 2820 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 4544 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 12441 | 0.010 |
Why?
|
| Orbit | 1 | 1995 | 457 | 0.010 |
Why?
|
| Adsorption | 2 | 1969 | 197 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1995 | 2264 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2009 | 5127 | 0.010 |
Why?
|
| Carbon Isotopes | 2 | 1969 | 458 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 81539 | 0.010 |
Why?
|
| Ligands | 1 | 1997 | 3272 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 9319 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 1995 | 932 | 0.010 |
Why?
|
| Chlamydia | 1 | 1969 | 33 | 0.010 |
Why?
|
| Maternal Behavior | 1 | 1991 | 307 | 0.000 |
Why?
|
| Animals | 3 | 2017 | 168475 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1968 | 299 | 0.000 |
Why?
|
| Thymidine | 1 | 1968 | 299 | 0.000 |
Why?
|
| Motor Skills | 1 | 1991 | 521 | 0.000 |
Why?
|
| Tritium | 1 | 1968 | 708 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 6534 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1968 | 531 | 0.000 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1995 | 1277 | 0.000 |
Why?
|
| Deoxyribonucleases | 1 | 1968 | 211 | 0.000 |
Why?
|
| Leucine | 1 | 1968 | 548 | 0.000 |
Why?
|
| Bile Acids and Salts | 1 | 1968 | 393 | 0.000 |
Why?
|
| Cell Line | 2 | 1997 | 15601 | 0.000 |
Why?
|
| Heparin | 2 | 1969 | 1634 | 0.000 |
Why?
|
| Brain | 1 | 2011 | 27121 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1997 | 18966 | 0.000 |
Why?
|
| Rats | 1 | 1995 | 23741 | 0.000 |
Why?
|
| Pregnancy | 1 | 1991 | 29890 | 0.000 |
Why?
|
| Haplorhini | 1 | 1969 | 525 | 0.000 |
Why?
|
| Amnion | 1 | 1969 | 197 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1969 | 2561 | 0.000 |
Why?
|
| Amino Acids | 1 | 1969 | 1718 | 0.000 |
Why?
|
| Bacterial Proteins | 1 | 1969 | 3847 | 0.000 |
Why?
|
| Kidney | 1 | 1969 | 7048 | 0.000 |
Why?
|